Suh H W, Song D K, Choi Y S, Kim Y H
Department of Pharmacology, College of Medicine, Hallym University, Kangwon-Do, South Korea.
Neuropeptides. 1996 Oct;30(5):485-90. doi: 10.1016/s0143-4179(96)90014-1.
The present study was designed to investigate the modulatory effects of blockade of spinal histamine receptors on antinociception induced by spinally administered morphine, beta-endorphin and U50, 488H. The effects of intrathecal (i.t.) injections with cyproheptadine (a histamine-1 (H1) receptor antagonist), ranitidine (an H2 receptor antagonist), or thioperamide (an H3 receptor antagonist) injected i.t., on the antinociception induced by morphine, beta-endorphin or trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl] benzeocetamide (U50, 488H) injected intrathecally (i.t.) were studied. The antinociception was assayed using the tail-flick test. The i.t. injection of cyproheptadine (20 micrograms), ranitidine (20 micrograms), or thioperamide (20 micrograms) alone did not produce any antinociceptive effect. i.t. pretreatment with cyproheptadine attenuated the inhibition of the tail-flick response induced by i.t. administered morphine or beta-endorphin, but not U50, 488H. In addition, i.t. pretreatment with ranitidine attenuated the inhibition of the tail-flick response induced by i.t. administered morphine, beta-endorphin, or U50, 488H. Furthermore, the i.t. pretreatment with thioperamide attenuated the inhibition of the tail-flick response induced by beta-endorphin or U50, 488H, but not morphine, administered i.t. Our results indicate that spinal H1 receptors may be involved in the production of antinociception induced by spinally applied morphine or beta-endorphin- but not U50, 488H. Spinal H2 receptors appear to be involved in spinally administered morphine-, beta-endorphin- and U50, 488H-induced antinociception. Supraspinal histamine H3 receptors may be involved in the production of antinociception induced by supraspinally applied beta-endorphin or U50, 488H, but not morphine.
本研究旨在探讨阻断脊髓组胺受体对脊髓注射吗啡、β-内啡肽和U50,488H诱导的镇痛作用的调节效应。研究了鞘内注射赛庚啶(一种组胺-1(H1)受体拮抗剂)、雷尼替丁(一种H2受体拮抗剂)或硫代哌酰胺(一种H3受体拮抗剂)对鞘内注射吗啡、β-内啡肽或反式-3,4-二氯-N-甲基-N-[2-(1-吡咯烷基)环己基]苯乙酰胺(U50,488H)诱导的镇痛作用的影响。采用甩尾试验测定镇痛作用。单独鞘内注射赛庚啶(20微克)、雷尼替丁(20微克)或硫代哌酰胺(20微克)均未产生任何镇痛作用。鞘内注射赛庚啶预处理减弱了鞘内注射吗啡或β-内啡肽诱导的甩尾反应抑制,但对U50,488H无影响。此外,鞘内注射雷尼替丁预处理减弱了鞘内注射吗啡、β-内啡肽或U50,488H诱导的甩尾反应抑制。此外,鞘内注射硫代哌酰胺预处理减弱了鞘内注射β-内啡肽或U50,488H诱导的甩尾反应抑制,但对吗啡无影响。我们的结果表明,脊髓H1受体可能参与脊髓应用吗啡或β-内啡肽诱导的镇痛作用,但不参与U50,488H诱导的镇痛作用。脊髓H2受体似乎参与鞘内注射吗啡、β-内啡肽和U50,488H诱导的镇痛作用。脊髓以上的组胺H3受体可能参与脊髓以上应用β-内啡肽或U50,488H诱导的镇痛作用,但不参与吗啡诱导的镇痛作用。